Roper Industries, Inc. — Form 10-Q Summary
Business context and period: The filing is for the unaudited quarter and six months ended June 30, 2014. The registrant named in the filing is Roper Industries, Inc.; this differs from the requested company name, Roper Technologies Inc. The company operates in Industrial Technology, Energy Systems & Controls, Medical & Scientific Imaging, and RF Technology.
Financial performance
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Net sales | $885.2 million | $784.0 million | $1,719.2 million | $1,521.1 million |
| Gross profit | $523.2 million | $445.5 million | $1,012.1 million | $867.1 million |
| Income from operations | $246.7 million | $179.7 million | $470.1 million | $364.9 million |
| Net earnings | $157.4 million | $111.4 million | $304.6 million | $236.3 million |
| Diluted EPS | $1.56 | $1.11 | $3.02 | $2.36 |
- Q2 sales rose 12.9%; management attributed growth to 8% organic growth and 5% from 2013 acquisitions. Gross margin expanded to 59.1% from 56.8%; net margin was 17.8% versus 14.2%.
- For the six months, sales increased 13.0%, gross margin was 58.9% versus 57.0%, and net earnings rose about 29%.
- Q2 segment sales growth was strongest in Medical & Scientific Imaging (+29.3%), followed by RF Technology (+10.0%), Energy Systems & Controls (+6.8%), and Industrial Technology (+3.7%). Medical & Scientific Imaging’s growth included 16% from acquisitions and 13% organic growth.
- Operating cash flow was $140.5 million in Q2, compared with $139.7 million; for the six months it was $353.1 million versus $311.0 million. Six-month capital expenditures were $20.6 million.
- At June 30, cash was $565.3 million, total debt was $2.245 billion, and net debt was $1.680 billion. Net debt to total net capital declined to 27.0% from 32.2% at December 31, 2013. Current assets were $1.525 billion and current liabilities $635.3 million.
- Six-month financing cash outflow was $226.3 million, including $220 million net repayment under the revolving credit line and $39.8 million of dividends. Debt fell from $2.465 billion at year-end.
Changes, outlook, and risks
- Growth and margin improvement were led by Medical & Scientific Imaging, where acquired businesses and higher-margin medical products and software contributed. Industrial Technology benefited from lower SG&A relative to sales, including the non-recurrence of a $9.1 million prior-year warranty expense.
- Management expected the 2014 effective tax rate to be approximately 31% and capital expenditures for the remainder of the year to be comparable to prior years as a percentage of sales. No specific full-year sales or earnings guidance is provided in the supplied filing text.
- Management expected operating cash flows to support debt reduction, but noted the pace would depend on acquisition financing needs and operating performance. It stated liquidity was sufficient for U.S. operating requirements for the foreseeable future; $492 million of cash at foreign subsidiaries was considered permanently reinvested, and repatriation could incur additional taxes. The company reported compliance with debt covenants.
- Orders were $873.9 million in Q2, up 7% year over year; backlog was $1.055 billion, up 3%. Management cited geopolitical uncertainty and risks from acquisitions and integration, indebtedness, currencies, interest rates, customer concentration, government contracts, competition, cyclicality, raw materials, warranty/product liability, and potential impairment of goodwill and intangibles.
- Legal matters include ordinary-course product liability and employment claims and asbestos-related litigation; management said it had made adequate provision for covered potential liabilities, but asbestos exposure could not be determined. Puerto Rico enacted a debt recovery law in July 2014 that could affect the outlook for the Puerto Rico Highways & Transportation Authority; management said it believed existing contracts and payable obligations would be honored.
- The company was evaluating the impact of the new revenue recognition standard. It reported no events requiring interim goodwill or indefinite-lived intangible impairment review and planned its annual review for the fourth quarter.
Key facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Roper Industries, Inc., although the request identifies Roper Technologies Inc.
- Assess how much growth and margin improvement is organic versus acquisition-related, particularly in Medical & Scientific Imaging.
- Track cash conversion, debt reduction, and the effect of cash held overseas and potential acquisition spending on liquidity.
- Monitor backlog conversion, customer concentration and government-contract exposure, including developments involving the Puerto Rico transportation authority.
- Review the expected tax rate, warranty and legal exposures, and the forthcoming annual impairment assessment of substantial goodwill and intangible assets.